Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27739028 | 0.90 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL5807509 | 0.90 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL27609514 | 0.90 | CNR1 (0.70) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL27591195 | 0.89 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL3687254 | 0.89 | CNR1 (0.85) | CNR1CNR2 | |
| SCHEMBL27591365 | 0.85 | CNR1 (0.65) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL27591161 | 0.85 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL27609619 | 0.84 | CNR1 (0.71) | CNR1CNR2 | |
| SCHEMBL4436286 | 0.81 | PTGS2 (0.54) | CNR1CNR2 | |
| SCHEMBL27609754 | 0.80 | CNR1 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| CN-101431994-A | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | CN | claimed |
| CN-101431998-A | Containing CBxPharmaceutical compositions of cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | CN | claimed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | claimed |
| EP-2012775-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| WO-2007125049-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| CN-101426197-A | Dynamic content distributing customer terminal in TD-SCDMA mobile terminal | SHANGHAI WINGTECH ELECTRONIC T (CN) | 2009-05-06 | — | — | CN | disclosed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR1 2/4885CNR2 1/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.